Organigram Holdings Stock Slips as Q3 Results Disappoint

Shares of Organigram Holdings Inc. (TSXV: OGI) have fallen more than 10% to its current price of $2.24 since the Company released its third-quarter results

SmallCapPower | August 4, 2017: Organigram Holdings Inc. (TSXV: OGI) reported financial results recently for the quarter ending May 31, 2017. Revenues increased just 6% to reach $1.9 million from $1.8 million in prior year quarter. This growth rate substantially lags its peers, which are showing double-digit growth. The dried marijuana sales stood at 196,217 grams (down 8% YoY), which is clearly a negative indicator for Organigram, which wants to cash in on the heavy demand when recreational marijuana becomes legalized in Canada in 2018. On the positive side, Organigram reported a 25% (QoQ basis) net increase in registered patients in the quarter.

For Our Complete Coverage Of Canadian Marijuana Stocks Click Here  

Shares of Organigram have fallen more than 10% to its current price of $2.24 since the Company released its third-quarter results on July 28, 2017.

Organigram Holdings’ financial results for the quarter completed May 31, 2017, included expenses associated with the implementation of an industry-leading quality assurance program (QA Program). Due to the implementation of the enhanced QA Program, which resulted in fewer products being introduced to the market than originally contemplated, Organigram recognized indirect production expenses of $1.1 million related to inventory destruction, and a loss of $1.6 million due to fair value adjustment to biological assets and net realizable reduction to inventory. As a result, Organigram generated adjusted EBITDA of ($1.5) million and cash flow of ($1.1) million.

Win Big With Our Small Cap Picks


The current results looks negative on the fundamental level, with lot of concern over the volumes of marijuana sold. Organigram is clearly falling behind as other marijuana companies are trying to capture the budding recreational marijuana market in Canada.

In terms of valuation, Organigram currently trades at price to sales value of 50.61x, price to book value of 2.86x and forward PE of 33.43x.

Disclosure: Neither the author nor any of the principals at Small Cap Power, or their family members, own shares in any of the companies mentioned above.

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. To read more of this Disclaimer please click on the button below: